anti-miR-132 agents nanoparticle (UCSD/Scripps Research Institute/Regulus)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameanti-miR-132 agents nanoparticle (UCSD/Scripps Research Institute/Regulus)
Drug Alias Nameanti-miR-132 antisense oligonucleotide (Regulus)anti-micro-RNA-132 agents nanoparticle (UCSD/Scripps Research Institute/Regulus)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNA
Mechanisms of ActionAngiogenesis inhibitors
TargetsUpdating
Therapy Area/IndicationsEye Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegulus Therapeutics IncUniversity Of California San DiegoThe Scripps Research Institute Inc
Active IndicationsN/A
Inactive IndicationsEye Diseases

Other Information

ATC CodeN/A
Related LinksN/A